⚠ Evidence note: Nutrition evidence is dominated by observational data with heavy confounding; trial endpoints are mostly surrogates, not lifespan.
Obesity and Adiposity in Aging
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-13 — Weight, Fat Mass, and Lean Mass Changes After Bariatric Surgery and GLP-1-Based Therapy: A Systematic Review and Meta-Analysis.: [human-observational] Meta-analysis of 30 human studies (>5,600 participants; underlying study designs not specified in the supplied summary) comparing surgery and GLP-1-based therapy found greater absolute fat and lean loss after surgery at 12 months without clearly demonstrating worse proportional lean preservation, distinguishing absolute from proportional body-composition changes without establishing equivalent preservation, sarcopenia risk, functional effects or longevity benefits. [human-observational] (novelty: 3)
- 2026-11-13 — Lepr Haploinsufficiency Accelerates Alzheimer-like Neurodegeneration via CDK5 Hyperactivation.: [animal-model] Genetic mouse study found that heterozygous leptin receptor deficiency (db/+) accelerated age-dependent metabolic dysfunction and Alzheimer-like neuropathology, implicating CDK5 hyperactivation alongside tau hyperphosphorylation and synaptic gene downregulation—preclinical metabolic, molecular and neuropathological endpoints, not human dementia-incidence or lifespan evidence, and not equivalent to ordinary obesity or therapeutic leptin blockade. [animal-model] (novelty: 3)
- 2026-11-14 — Disruptions in and continued absence of different social ties and the risk of central obesity: a prospective investigation of women and men in the CLSA (2011-2021).: [human-observational] Prospective Canadian Longitudinal Study on Aging analysis in middle-aged and older adults associated persistent absence of diverse social participation over three years with higher odds of incident central obesity in women—an anthropometric adiposity endpoint, not evidence of downstream disease incidence or mortality effects, causality, or benefit from increasing social participation. [human-observational] (novelty: 3)
- 2026-11-11 — Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.: [human-rct] COURAGE, a two-part phase 2 double-blind placebo-controlled RCT (n=975) in adults with obesity receiving semaglutide, found that adding trevogrumab (anti-GDF8/myostatin) significantly attenuated lean-mass loss with reported good tolerability, whereas adding both trevogrumab and garetosmab (anti-activin A) further improved body composition but produced unacceptable adverse events—body-composition surrogate findings and clinical safety outcomes, not evidence of preserved strength, prevented sarcopenia, reduced disease incidence or longer lifespan. [human-rct] (novelty: 4)
- 2026-11-10 — Nutrition Care Strategies at the Intersection of Menopause and Obesity Pharmacotherapy.: [expert-opinion] Menopause-focused clinical review flags potentially overlapping effects of estrogen decline and incretin-associated appetite suppression on muscle and bone, without new primary data establishing accelerated sarcopenic obesity or osteoporosis, equating lean-mass loss with sarcopenia, or demonstrating fracture or longevity effects. [expert-opinion] (novelty: 3)
- 2026-11-09 — n-3 polyunsaturated fatty acids ameliorate obesity with cognitive impairment by promoting adipose browning and remodeling of brain lipid metabolism.: [animal-model] Dietary fish oil reduced adiposity and improved cognitive performance in an Alzheimer’s mouse model, alongside adipose-browning markers UCP1 and Prdm16 and brain lipid remodeling toward lower ceramides and greater phospholipid enrichment—preclinical metabolic, behavioral and molecular endpoints, not evidence of reduced human dementia incidence or longer lifespan. [animal-model] (novelty: 3)
- 2026-08-07 — MDM2 deletion and its associated p53 activation in subcutaneous white adipose tissue induce hepatic fibrosis via galectin-3 in a mouse model.: [animal-model] Mouse genetic study found that selective MDM2 deletion with sustained p53 activation in subcutaneous white adipose tissue induced adipocyte senescence and promoted hepatic fibrosis via increased adipocyte-derived galectin-3 secretion—a liver-pathology outcome in an engineered model, not evidence that ordinary adiposity causes this pathway in humans or that dietary intervention improves longevity. [animal-model] (novelty: 3)
- 2026-08-16 — Dynapenic obesity and incident cross-domain multimorbidity: A prospective study of three ageing cohorts.: [human-observational] Prospective observational analysis harmonizing CHARLS, HRS and ELSA (n=15,207) associated dynapenic obesity—obesity with low muscle strength—with higher incident cross-domain multimorbidity, including more than three-fold risk of concurrent somatic disease, depressive symptoms and cognitive impairment; this combines disease and symptom/impairment outcomes rather than aging biomarkers alone, but does not establish causality, dementia incidence, mortality effects or benefits from weight loss or strength gains. [human-observational] (novelty: 3)
- 2026-09-06 — Joint Effects of Long-Term Obesity and Genetic Susceptibility on Sex-Specific Brain Aging.: [human-observational] Longitudinal UK Biobank observational study of over 35,000 participants examining 16-year obesity trajectories associated persistent obesity with greater multimodal brain-age acceleration, more strongly in males than females, and transition from obesity to non-obesity with 18–30% lower accelerated-brain-aging risk; these are imaging-derived surrogate findings, not dementia-incidence or mortality outcomes, and do not establish that intentional weight loss reverses brain aging. [human-observational] (novelty: 3)
- 2026-10-12 — Biological Aging, Adiposity, and Inflammation in Degenerative Spine Disease: Mendelian Randomization and Longitudinal United Kingdom Biobank Analyses.: [human-observational] Longitudinal UK Biobank analyses combined with Mendelian randomization support causal roles for adiposity and systemic inflammation indexed by CRP in degenerative spine disease, conditional on genetic-instrument assumptions, while finding no support for a causal role of leukocyte telomere length despite its observational association—a disease outcome rather than an aging-biomarker improvement, without evidence that weight loss or inflammation reduction prevents spinal degeneration or extends lifespan. [human-observational] (novelty: 3)
- 2026-10-13 — Regional oxygen extraction fraction is higher in older adults with type 2 diabetes and obesity: associations with cognition and metabolic markers.: [human-observational] Human observational pilot study found elevated regional QSM MRI-derived cerebral oxygen extraction fraction in older adults with co-occurring type 2 diabetes and obesity, associated with worse executive-function performance and altered adipokine levels—imaging, metabolic and cognitive-test findings, not evidence of incident dementia, mortality effects, causality or benefit from weight loss or glucose lowering. [human-observational] (novelty: 3)
- 2026-10-15 — Combined impact of dynapenic abdominal obesity on stroke risk in middle-aged and older adults: evidence from two nationwide prospective cohorts.: [human-observational] Two nationwide prospective cohorts (CHARLS and ELSA, total N >15,500) associated dynapenic abdominal obesity—low muscle strength combined with abdominal obesity—with roughly doubled seven-year incident stroke risk and greater risk than either feature alone, a disease-incidence outcome rather than a surrogate, without establishing causality or showing that reducing waist size or increasing strength prevents stroke. [human-observational] (novelty: 3)
- 2026-10-01 — TyG-ABSI and TyG-WWI as insulin-resistance body shape markers of mortality in middle-aged and older adults within the cardiovascular-kidney-metabolic framework: A multi-cohort observational study with external survival-model validation.: [human-observational] Multi-cohort observational analysis of NHANES, ELSA, CHARLS and HRS, with external survival-model validation, found that TyG-ABSI and TyG-WWI composite triglyceride-glucose/body-shape indices consistently associated with all-cause mortality in middle-aged and older adults—a clinical outcome rather than a surrogate—but added little predictive discrimination beyond standard clinical risk factors and did not establish that lowering these indices reduces mortality. [human-observational] (novelty: 3)
- 2026-10-17 — Heavy inheritance: Genetic pathways from excess weight to biological aging and health in old age.: [human-observational] Human observational instrumental-variable analysis using polygenic risk scores and gene–environment interactions estimated a 4–5% relative increase in the frailty index per additional BMI unit in older adults, supporting a causal interpretation conditional on instrument validity but measuring accumulated health deficits rather than mortality or disease incidence and not establishing that intentional weight loss reverses frailty or extends lifespan. [human-observational] (novelty: 3)
- 2026-10-22 — Sustained Versus Minimal GLP-1 Receptor Agonist Exposure and Metabolic Outcomes in Older Adults Without Diabetes.: [human-observational] Real-world observational study (N=13,387) in adults aged 65+ with obesity and without diabetes associated sustained versus minimal GLP-1 receptor agonist exposure with greater BMI and HbA1c reductions (surrogates) and approximately half the incident diabetes (a disease-incidence outcome), without establishing causality or a longevity benefit. [human-observational] (novelty: 3)
- 2026-10-23 — Leptin Neutralization Attenuates Inflammaging in Endothelial and Immune Cell Models.: [mechanism-plausible] Endothelial and immune cell experiments implicate leptin–mTOR signaling in cellular senescence and the senescence-associated secretory phenotype (SASP), with leptin receptor blockade reducing senescence and inflammatory markers—cellular endpoints, not evidence of reduced disease incidence or longer lifespan in humans. [mechanism-plausible] (novelty: 3)
- 2026-10-26 — Dissecting the shared genetic architecture of adipose tissue aging and aging-related lipid-metabolic dysfunction: a multivariate genomic analysis.: [human-observational] Human multivariate genomic analysis using Genomic SEM constructed mvAdiposeAge, a latent genetic factor spanning fat distribution, ectopic lipid accumulation and metabolic dysregulation, identified prominent FTO-locus signals and brain/neurotrophin-pathway enrichment, and found genetic associations with adiposity and lower cognitive performance—genetic and trait-level findings, not proof that adipose aging causes cognitive decline or evidence of effects on dementia incidence or lifespan. [human-observational] (novelty: 3)
- 2026-10-21 — Associations of longitudinal patterns of central obesity and chronic low-grade inflammation with incident frailty in middle-aged and older adults.: [human-observational] Prospective longitudinal trajectory study in over 7,000 middle-aged and older adults associated persistent central obesity and elevated C-reactive protein independently and jointly, with reported synergy, with incident frailty—a clinical outcome rather than a biomarker alone—and found central adiposity temporally preceded inflammation, without establishing causality or showing that reducing either exposure prevents frailty or extends lifespan. [human-observational] (novelty: 3)
- 2026-11-04 — Longitudinal associations between the hallmarks of aging and body composition: a narrative review.: [human-observational] Narrative review of 50 longitudinal human studies finds that evidence linking aging hallmarks to muscle, bone, and adipose remodeling is concentrated in deregulated nutrient sensing and chronic inflammation, with major gaps for cellular senescence, epigenetic alterations, and autophagy; these body-composition associations do not establish causality or demonstrate reduced disease incidence or longer lifespan. [human-observational] (novelty: 3)
- 2026-11-03 — Impact of sarcopenic obesity phenotype on long-term survival in geriatric trauma: A nationwide cohort study using weight-adjusted waist index.: [human-observational] Nationwide cohort study (n=18,366) of older adults with severe trauma reported an adjusted association between high Weight-Adjusted Waist Index (WWI) and 72% higher mortality over 20 years—a clinical outcome, not a biomarker endpoint—but WWI is an anthropometric proxy rather than a direct sarcopenic-obesity diagnosis, and this association neither establishes causality nor definitively resolves the BMI obesity paradox. [human-observational] (novelty: 3)
- 2026-11-05 — Resistant hypertension and accelerated vascular aging: evidence for PTEN-AKT-associated cellular senescence.: [human-observational] Human observational evidence links resistant hypertension in older adults and individuals with obesity to accelerated vascular-aging and endothelial-senescence markers, without establishing obesity as the cause or demonstrating effects on mortality or disease incidence. [human-observational] (novelty: 3)
- 2026-10-29 — Metabolic exhaustion underlies sarcopenic obesity susceptibility in aging mice as revealed by multi-omics factor analysis.: [animal-model] Multi-omics factor analysis in aging mice implicated skeletal-muscle metabolic exhaustion and incomplete beta-oxidation, rather than obesity severity, in sarcopenic-obesity susceptibility and identified circulating acetylcarnitine and pantothenol as candidate discriminatory biomarkers; these are preclinical phenotype and biomarker findings, not validated human predictors or evidence of longevity benefit. [animal-model] (novelty: 3)
- 2026-11-02 — Sex Hormones as Regulators of the Age- and Sex-Dependent Benefits of Caloric Restriction: An Emerging Research Protocol of a Controlled Dietary Intervention (The GendAge Weight Loss Study).: [expert-opinion] GendAge controlled-feeding study protocol, with no outcome data reported, identifies age, biological sex, and postmenopausal estrogen/HRT status as candidate modifiers of fat-loss and metabolic responses to caloric restriction, without establishing subgroup differences or clinical benefits. [expert-opinion] (novelty: 3)
- 2026-10-29 — Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.: [expert-opinion] Review applies the Geriatrics 5Ms framework to incretin-based obesity prescribing in older adults, emphasizing structured geriatric assessment and patient priorities when balancing cardiometabolic benefits against potential lean-mass loss, frailty and functional decline; no new primary outcome data or longevity evidence. [expert-opinion] (novelty: 3)
- 2026-10-01 — Tirzepatide and the prevention of heart failure in obesity: a multi-center cohort study using the TriNetX database.: [human-observational] Multicenter TriNetX propensity-matched cohort study involving over 380,000 adults with obesity associated tirzepatide use with 47% lower new-onset heart failure, 69% lower 1-year all-cause mortality, and fewer major adverse cardiovascular events—clinical outcomes rather than surrogates, but residual confounding prevents causal conclusions about treatment benefit or lifespan extension. [human-observational] (novelty: 3)
- 2026-10-28 — Normal-BMI MASLD is Associated with Increased Mortality, Cardiovascular Events, Cancer and Lower GLP-1 Use.: [human-observational] A propensity-matched cohort study found higher mortality, cardiovascular events and cancer among patients with normal-BMI MASLD than among those with obesity-associated MASLD, alongside less frequent incretin-based therapy prescribing and an association between therapy use and better survival; these are clinical outcomes rather than surrogate biomarkers, but residual confounding precludes causal conclusions about BMI or treatment benefit. [human-observational] (novelty: 3)
- 2026-07-30 — Complementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: genetic evidence from large-scale phenomic analyses.: UK Biobank TreeWAS plus factorial Mendelian randomization: genetically predicted higher physiological GLP-1 combined with lower GIP associated with complementary reductions in obesity, CVD, venous thromboembolism, and hepatic events, with body weight as a plausible mediator and no bone-metabolism harm signal — genetic-instrument evidence informing the GIP-agonist vs antagonist debate, not a trial readout. [human-observational] (novelty: 3)
- 2026-10-06 — The Effect of a Very Low-Carbohydrate Diet on Intermuscular Adipose Tissue and Muscle Function in Older Adults With Obesity.: Small 8-week weight-maintaining RCT in older adults with obesity: very low-carb vs low-fat diet produced large thigh IMAT reduction (−24.4% vs −1.0%) at stable body weight, and IMAT change tracked with grip, knee extension, and reach gains — dissociates ectopic muscle fat from total adiposity as a functional lever. [human-rct] (novelty: 3)
- 2026-10-07 — Weight Loss or Muscle Loss? Cellular Mechanisms and Clinical Strategies for Preserving Lean Mass During GLP-1-Based Therapy.: Review of GLP-1-based obesity therapy reframes success as fat loss plus preserved muscle mass and function, distinguishing lean-mass reduction (partly non-contractile) from pathological skeletal muscle loss and highlighting older adults as the population where the distinction matters most; opinion synthesis, no new primary data. [expert-opinion] (novelty: 3)
- 2026-10-02 — Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics.: Polish Society of Dietetics scientific statement frames dietitian-led nutritional care during incretin-based obesity therapy as essential to preserve lean mass and prevent nutrient shortfalls alongside pharmacological adiposity reduction; society position, no new primary data. [expert-opinion] [expert-opinion] (novelty: 3)
- 2026-04-03 — EffectS of Lifestyle Interventions in Older PEople With Obesity (Effective SLOPE): a Systematic Review With Network Meta-Analyses.: Effective SLOPE network meta-analysis of 72 RCTs (54 in NMA) in community-dwelling older adults with obesity ranks combined nutrition + exercise + behavior-change interventions as most suitable for improving physical function and reducing body/fat mass without clear harm to fat-free mass or bone mineral density — comparative synthesis of lifestyle lever combinations, surrogate and functional endpoints only. [human-rct] (novelty: 3)
- 2026-10-01 — Joint trajectories of abdominal obesity and systolic blood pressure are associated with incident stroke in two prospective cohorts.: Joint multi-trajectory analysis in two aging cohorts (HRS, ELSA) found additive associations of waist-to-height ratio and systolic blood pressure trajectories with incident stroke, with severe abdominal obesity carrying the highest stroke risk even without markedly elevated SBP — extends central-adiposity stroke-risk signal to joint BP co-trajectories, observational replication only. [human-observational] (novelty: 3)
- 2026-06-09 — DXA-derived regional adiposity identifies hidden liver-metabolic risk beyond BMI in non-obese older adults: A cross-sectional study.: Cross-sectional study in non-obese older adults: DXA-derived visceral adipose tissue (and low-muscle/high-VAT phenotypes) independently associated with elevated fatty-liver/hepatic-steatosis indices and liver enzymes beyond BMI, with waist circumference serving as a feasible proxy when DXA is unavailable — reinforces that BMI misses regional-adiposity-driven hepatic-metabolic risk in lean older adults, surrogate biomarkers only. [human-observational] (novelty: 3)
- 2026-06-27 — A prospective cohort study on the independent and combined effects of body mass status and grip strength on premature mortality risk among older adults.: UK Biobank prospective cohort in older adults applying EASO obesity framework plus grip strength: EASO-defined underweight and obesity raised premature mortality, overweight was associated with lower risk, abnormal grip strength independently raised risk, and underweight + weak grip conferred ~5× higher premature mortality — reinforces the obesity-paradox pattern and the muscle-function × adiposity interaction, mortality-based but observational. [human-observational] (novelty: 3)
- 2026-07-27 — Global and regional projections of atherosclerotic cardiovascular-kidney-liver-metabolic disease burden to 2050: a forecasting analysis for the global burden of disease study 2023.: GBD-2023 forecasting analysis projects metabolic antecedents (T2DM, CKD, MASLD, obesity) will roughly double by 2050 and expand from ~one-third to nearly half of total cardiovascular-kidney-liver-metabolic (CKLM) burden — population-level projection reinforcing adiposity as a dominant contributor to future disease burden, not an outcome trial. [human-observational] (novelty: 3)
- 2026-08-26 — Joint trajectories of body mass index and depressive symptoms and incident liver disease: A multicohort study with frailty mediation analysis.: Multicohort prospective joint-trajectory analysis: obesity + moderate depression and normal-weight + high depression trajectories associated with ~2–3.5× higher incident liver disease vs normal-weight + low depression, partially mediated by frailty accumulation — extends adiposity-trajectory risk signal into liver disease and links it to a psychiatric co-trajectory with frailty as mediator. [human-observational] (novelty: 3)
- 2026-09-30 — Sex- and age-specific patterns in bone, muscle, and fat across adulthood and their relation to osteosarcopenic adiposity phenotype: a cross-sectional study.: Cross-sectional LOESS mapping in ~9,700 adults: bone, muscle, fat, and IMAT follow sex-specific nonlinear age trajectories (earlier male peaks, sharper female midlife declines around menopause), and adults meeting BIA-ACC osteosarcopenic adiposity criteria show less stable trajectories and earlier musculoskeletal decline — extends the osteosarcopenic/sarcopenic-obesity phenotype signal with age- and sex-specific inflection mapping. [human-observational] (novelty: 3)
- 2026-09-30 — Nonlinear association between waist-to-height ratio and Alzheimer’s disease among middle-aged and older adults: A cross-sectional study from NHANES.: Cross-sectional NHANES analysis of middle-aged and older adults: higher waist-to-height ratio associated with greater odds of Alzheimer’s disease in a nonlinear U-shaped pattern (lowest odds near scaled WHtR ~5.46) — extends the central-adiposity → dementia association signal with a dose-shape refinement, cross-sectional and prevalent-case only. [human-observational] (novelty: 3)
- 2026-10-01 — Consensus-Defined Sarcopenic Obesity and a Related Dynapenic Obesity Phenotype in Relation to Early Cognitive Impairment.: Prospective cohort in non-demented older adults: consensus-defined sarcopenic obesity and a related dynapenic-obesity phenotype were associated with poorer global cognition, memory, and attention — extends the sarcopenic-obesity harm signal to cognitive domains using harmonized definitions, cross-sectional associational only. [human-observational] (novelty: 3)
- 2026-09-28 — Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern.: 2026 perspective review reframes incretin-associated lean-mass loss as physiological body-composition remodeling comparable to other effective weight-loss modalities — preferential fat loss with preserved or improved physical function — rather than pathological sarcopenia; conceptual synthesis, no new primary data. [expert-opinion] (novelty: 3)
- 2026-10-01 — Associations of Life’s Essential 10 with Mortality and Healthspan Free of Cardiovascular Disease and Cancer: Findings in Two Nationwide Cohorts.: 2026 UK Biobank + NHANES prospective analysis of Life’s Essential 10 (which includes BMI as one of ten components) found higher composite CVH scores associated with lower all-cause, CVD and cancer mortality and multi-year gains in disease-free life expectancy — adiposity contribution is embedded in the composite and not separable here. [human-observational] (novelty: 3)
- 2026-09-21 — Can Obesity Pharmacotherapy Modify Osteoarthritis? Interpreting Pain Relief, Weight-Loss Quality, and Structural Outcomes.: 2026 narrative review of obesity pharmacotherapy in osteoarthritis: GLP-1 and multi-agonist weight loss delivers substantial OA pain relief in class-III obesity RCTs but shows no evidence of structural joint modification and raises concerns about fat-vs-muscle/bone weight-loss quality — reframes pharmacological adiposity reduction as symptomatic, not disease-modifying, and reinforces the lean-mass-preservation caveat. [expert-opinion] (novelty: 3)
- 2026-09-25 — An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss.: Preclinical mouse study: adipose-directed ZFP423 antisense oligonucleotides induced white-adipose beiging/thermogenesis and, combined with semaglutide, produced greater fat loss while preserving lean mass vs semaglutide alone — a candidate mechanistic route to decouple GLP-1 adiposity reduction from sarcopenic lean-mass loss, mouse-only. [animal-model] (novelty: 4)
- 2026-09-15 — Biological signature of dietary patterns in older adults: findings from a population-based study.: Cross-sectional older-adult analysis: higher adherence to Mediterranean, AHEI, and anti-inflammatory dietary patterns associated with more favourable metabolic and inflammatory blood biomarkers — reinforces diet-quality → cardiometabolic-biomarker signal but does not test adiposity mediation directly. [human-observational] (novelty: 3)
- 2026-09-22 — Sarcopenic obesity is associated with more severe functional impairment and lumbar degeneration in patients with degenerative lumbar spinal stenosis.: Cross-sectional DLSS patient study: sarcopenic obesity independently associated with greater functional impairment and more severe lumbar disc, foraminal, Modic, and paraspinal-muscle degeneration, with fat mass amplifying sarcopenia’s adverse effects — extends the sarcopenic-obesity phenotype’s musculoskeletal harm signal to spinal degeneration. [human-observational] (novelty: 3)
- 2026-09-22 — Clinical obesity phenotypes among older adults: prevalence, determinants, and morbidity burden from the Longitudinal Ageing Study in India.: LASI Wave 1 cross-sectional analysis (~60k Indians ≥45) operationalizes the 2025 Lancet clinical obesity framework: 15.0% preclinical and 22.5% clinical obesity, with higher odds in women, urban/wealthier, and socially isolated groups and excess cardiometabolic multimorbidity vs non-obese — first national-scale prevalence estimate under the new framework, associational only. [human-observational] (novelty: 3)
- 2026-09-23 — A probioticconverts hesperidin to bioactive hesperetin and improves metabolic dysfunction in aging mice.: Aging mice on Western diet: probiotic CL256B + hesperidin (→hesperetin) reduced adiposity and hepatic steatosis and improved grip strength via CISD2 pathway — mouse-level surrogate improvements in diet-induced adiposity, not human outcome data. [animal-model] (novelty: 3)
- 2026-09-18 — Ferroptosis and Ferro-Aging in Obesity: Bibliometric Mapping, Shared Mechanisms, and Translational Perspectives.: 2026 bibliometric review proposes a ferroptosis→ferro-aging continuum in obesity, with ACSL4-driven lipid peroxidation and Nrf2–GPX4 antioxidant collapse as candidate hubs linking adipose iron overload to chronic senescence; conceptual synthesis of prior literature, no new primary data. [mechanism-plausible] (novelty: 3)
- 2026-06-01 — Adipose tissue as a systemic modulator of brain aging: mechanistic links between metabolism, inflammation and neurodegeneration.: 2026 integrative review frames visceral adipose tissue as a systemic driver of brain aging via chronic inflammation, insulin resistance, adipokine imbalance, SASP and adipose-derived vesicles, while subcutaneous and thermogenic depots are positioned as potentially protective — mechanistic synthesis of epidemiological, neuroimaging and experimental literature, no new primary data. [mechanism-plausible] (novelty: 3)
- 2026-06-08 — ACAT3 controls hepatic cholesterol metabolism and modulates systemic energy homeostasis of male mice.: Mouse genetic study: hepatic ACAT3 modulates cholesterol/bile-acid metabolism, gut microbiota, and systemic energy homeostasis in male mice, with ACAT3 expression downregulated in obesity, diabetes, and aging — positions a liver enzyme as a candidate mechanistic node linking adiposity to metabolic aging, mechanism only, no outcome data. [animal-model] (novelty: 3)
- 2026-08-19 — Co-evolving adiposity and frailty trajectories shape stroke risk in middle-aged and older adults.: Four-cohort joint BMI–frailty trajectory analysis in middle-aged and older adults: co-evolving adiposity+frailty trajectories stratify incident stroke risk better than either alone, with obesity+high frailty highest-risk and overweight+low frailty appearing protective — extends the obesity paradox by showing frailty status modifies adiposity-stroke associations. [human-observational] (novelty: 3)
- 2026-09-15 — Metabolic and Bariatric Surgery and Change in the AI-ECG-Derived Biological-Age Gap: A Longitudinal Cohort Study.: Same MBS cohort separates chronic adiposity from within-person weight change: cumulative adiposity — not weight loss trajectory — tracks with higher AI-ECG δage, echoing prior CLHLS findings that cumulative BMI/WC exposures drive biological-age surrogates more than short-term change. [human-observational] (novelty: 3)
- 2026-09-15 — Dietary composition and metabolic stress differentially affect the ovarian microenvironment in mice.: Mouse study: Western and high-fat diets drive ovarian stromal collagen deposition and microenvironment remodeling before ovarian reserve depletion or oocyte-number changes, extending diet-adiposity-fibrosis links to the reproductive compartment. [animal-model] (novelty: 3)
- 2026-09-01 — Comparative mediation roles of body shape indices in the association between Healthy Eating Index-2015 and phenotypic age acceleration: A cross-sectional study based on NHANES 2005-2010.: cross-connection with healthy-eating-index: NHANES 2005–2010 mediation analysis finds central-adiposity indices (waist-to-height ratio, Body Roundness Index) partially mediate the HEI-2015 → lower PhenoAge acceleration association, positioning central adiposity as a pathway between diet quality and biological-age surrogates. [human-observational] (novelty: 3)
- 2026-09-09 — Weight Loss and Physical Activity Reduces Perceived Physical Fatigability Among Older Adults With Obesity.: 18-month multi-arm RCT (N=183) in older adults with obesity: dietary weight loss plus aerobic exercise, daylong movement, or both produced clinically relevant reductions in perceived physical fatigability that were largely maintained at 18 months — a patient-reported functional surrogate, not disease incidence or mortality. [human-rct] (novelty: 3)
- 2026-09-10 — A vascular-muscle-adiposity phenotype and incident stroke risk in middle-aged and older adults: a multi-cohort study.: Multi-cohort observational analysis (CHARLS, ELSA, HRS) finds a rule-based vascular-muscle-adiposity phenotype (high MAP + low grip strength + high waist-to-height ratio) associated with ~30% higher incident stroke hazard per adverse dimension and near-doubled risk at 3 vs 0 dimensions — reinforces waist-to-height ratio (central adiposity) as a component of a composite stroke-risk phenotype, though the phenotype itself is multi-domain rather than adiposity-specific. [human-observational] (novelty: 3)
- 2026-09-11 — Divergent amino acid profiles in sarcopenic obesity versus non-obese sarcopenia: A prospective cohort study in community-dwelling older adults.: cross-connection with protein-intake: Prospective cohort shows amino-acid–sarcopenia associations flip sign depending on adiposity status (BCAAs/AAAs harmful in sarcopenic obesity, protective in non-obese sarcopenia), tying obesity phenotype to protein/amino-acid handling in aging. [human-observational] (novelty: 3)
- 2026-09-12 — Impact of caloric restriction on biological aging: insights from a composite biomarker index in older adults.: cross-connection with caloric-restriction: Pooled CR RCT analysis finds only about half of the composite biological-aging biomarker improvement is mediated by weight loss, partially dissociating CR’s aging-biomarker effects from adiposity reduction. (novelty: 3)
- 2026-07-21 — Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide: 2026 — Trial protocol pairs lifestyle intervention (exercise + nutrition) with semaglutide-driven weight loss in older T2D patients to test whether sarcopenic side effects of pharmacological adiposity reduction can be mitigated; aims description, no outcome data. [expert-opinion] (novelty: 3)
- 2026-06-29 — #398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss: cross-connection with protein-intake: Protein sufficiency plus resistance training is positioned as the lever that decouples GLP-1-driven adiposity reduction from sarcopenic lean-mass loss. (novelty: 3)
- 2026-03-25 — Senolytic therapy ameliorates high-fat diet-induced hippocampal senescence and cognitive decline in mice.: Mouse study extends adiposity→senescence framing to brain: HFD-driven hippocampal senescence and cognitive decline reversed by D+Q senolytics, consistent with the senolytic rung of the prevention ladder proposed in the 2026 metainflammation review. [animal-model] (novelty: 3)
- 2026-08-05 — The Immunometabolic Bridge: Targeting Metainflammation to Prevent the Transition from Obesity to Cardiovascular Disease.: 2026 narrative review proposes adipose-derived metainflammation as an immunometabolic bridge from preclinical obesity to CVD, only pathogenic in a permissive metabolic milieu, and sketches a tiered prevention ladder (lifestyle/statins → GLP-1 agonists → senolytics); conceptual synthesis, no new primary data. [mechanism-plausible] (novelty: 3)
- 2026-08-01 — Cardiometabolic Aging Driven by Multi-Organ Crosstalk: Mechanisms and Therapeutic Strategies.: 2026 narrative review on cardiometabolic aging frames adipose–heart crosstalk (adipokine dysregulation, ectopic fat, inflammation) as one node feeding cardiac senescence via shared oxidative stress/autophagy/senescence pathways; mechanistic synthesis, no new outcome data. [mechanism-plausible] (novelty: 3)
- 2026-08-20 — The impact of cumulative obesity and genetic susceptibility on biological aging in Chinese older adults.: CLHLS multi-wave cohort of Chinese older adults: cumulative BMI and cumulative waist circumference exposures positively associated with KDM-biological age acceleration and physiological dysregulation (surrogate aging markers, not mortality); cWC effect stronger in those with low polygenic longevity score. [human-observational] (novelty: 3)
Open questions
Related
Contributing findings
Disruptions in and continued absence of different social ties and the risk of central obesity: a prospective investigation of women and men in the CLSA (2011-2021).
14-nov-2026
novelty 3
per-area 3
strengthens
Weight, Fat Mass, and Lean Mass Changes After Bariatric Surgery and GLP-1-Based Therapy: A Systematic Review and Meta-Analysis.
13-nov-2026
novelty 3
per-area 3
strengthens
Metabolic syndrome and Alzheimer's disease: Mechanistic links and precision prevention (Review).
13-nov-2026
novelty 2
per-area 2
strengthens
Lepr Haploinsufficiency Accelerates Alzheimer-like Neurodegeneration via CDK5 Hyperactivation.
13-nov-2026
novelty 3
per-area 3
strengthens
Premature immune aging in obesity: a testable framework linking immunosenescence, metaflammation, and multiorgan dysfunction.
12-nov-2026
novelty 2
per-area 2
weakens
Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.
11-nov-2026
novelty 4
per-area 4
strengthens
Effect of subnormal estimated glomerular filtration rate on mortality varies by obesity metrics: a two-dimensional exposure-response analysis.
11-nov-2026
novelty 2
per-area 2
strengthens
Urinary Incontinence, Obesity, Quality of Life, and Loneliness in Older Adults: An Observational Study.
10-nov-2026
novelty 2
per-area 2
strengthens
Associations between sarcopenic obesity subtypes, cognitive function and neurodegenerative diseases risk in middle-aged and older adults.
10-nov-2026
novelty 3
per-area 2
strengthens
Nutrition Care Strategies at the Intersection of Menopause and Obesity Pharmacotherapy.
10-nov-2026
novelty 3
per-area 3
strengthens
Evidence generation for diabetes prevention and treatment through the integration of clinical medicine, nutritional epidemiology, and behavioral science.
10-nov-2026
novelty 2
per-area 2
strengthens
Sarcopenic Obesity: Estimation of Prevalence and Identification of Clinical and Biological Determinants in a Population of Adult Obese Patients
10-nov-2026
novelty 2
per-area 2
mentions
n-3 polyunsaturated fatty acids ameliorate obesity with cognitive impairment by promoting adipose browning and remodeling of brain lipid metabolism.
09-nov-2026
novelty 3
per-area 3
strengthens
Body composition in octogenarians with chronic kidney disease. Role of gender.
07-nov-2026
novelty 2
per-area 2
strengthens
Resistant hypertension and accelerated vascular aging: evidence for PTEN-AKT-associated cellular senescence.
05-nov-2026
novelty 3
per-area 3
strengthens
Obesity pharmacotherapies and cognition.
05-nov-2026
novelty 3
per-area 2
mentions
Adiposity measures in relation to cognitive screening performance and MRI-derived brain age gap in middle-aged and older adults.
05-nov-2026
novelty 2
per-area 2
strengthens
Obesity Indicators and Bone Density/Osteoporosis in Older Adults: Sex-Stratified Spline Analysis.
04-nov-2026
novelty 2
per-area 2
strengthens
Longitudinal associations between the hallmarks of aging and body composition: a narrative review.
04-nov-2026
novelty 3
per-area 3
strengthens
Impact of sarcopenic obesity phenotype on long-term survival in geriatric trauma: A nationwide cohort study using weight-adjusted waist index.
03-nov-2026
novelty 3
per-area 3
strengthens
Height, Weight, and BMI Muscle Mass Adjustment for Sarcopenic Obesity: Differential Associations with Functional Outcomes among Healthy Asian Older Adults.
02-nov-2026
novelty 2
per-area 2
strengthens
Sex Hormones as Regulators of the Age- and Sex-Dependent Benefits of Caloric Restriction: An Emerging Research Protocol of a Controlled Dietary Intervention (The GendAge Weight Loss Study).
02-nov-2026
novelty 3
per-area 3
strengthens
Possible sarcopenia, abdominal obesity, and all-cause mortality in middle-aged and older adults with chronic kidney disease: a dual-cohort study.
01-nov-2026
novelty 2
per-area 2
weakens
Biological functions and emerging interplay of FGF21 and GDF15 in metabolic diseases and aging.
30-oct-2026
novelty 2
per-area 2
strengthens
Glucagon-Like Peptide-1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction.
30-oct-2026
novelty 3
per-area 2
strengthens
Metabolic exhaustion underlies sarcopenic obesity susceptibility in aging mice as revealed by multi-omics factor analysis.
29-oct-2026
novelty 3
per-area 3
strengthens
Intervening in Adipocyte Senescence: Lipid Prodrugs as an Emerging Strategy for Metabolic Disease Treatment.
29-oct-2026
novelty 3
per-area 2
strengthens
Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.
29-oct-2026
novelty 3
per-area 3
strengthens
Corrigendum to "Effect of aerobic or resistance exercise, or both on insulin secretion, ciliary neurotrophic factor, and insulin-like growth factor-1 in dieting older adults with obesity" [Clin Nutr 51 (2025) 50-62].
28-oct-2026
novelty 1
per-area 1
mentions
Mediterranean Diet Adherence and Cognitive Function in Older Adults: Heterogeneity in the Association Across BMI Categories.
28-oct-2026
novelty 2
per-area 2
strengthens
Normal-BMI MASLD is Associated with Increased Mortality, Cardiovascular Events, Cancer and Lower GLP-1 Use.
28-oct-2026
novelty 3
per-area 3
strengthens
The use of glucagon-like peptide-1 agonists as a treatment for obesity in older people: risks and benefits.
27-oct-2026
novelty 2
per-area 2
strengthens
Dissecting the shared genetic architecture of adipose tissue aging and aging-related lipid-metabolic dysfunction: a multivariate genomic analysis.
26-oct-2026
novelty 3
per-area 3
strengthens
Identification of TAS2R-targeting bioactive compounds against metabolic decline: A novel ex vivo methodology based on enteroendocrine and inflammatory readouts.
26-oct-2026
novelty 3
per-area 2
strengthens
The associations of triglyceride-cholesterol-body weight index and relative handgrip strength with new-onset frailty: evidence from two prospective cohort studies.
24-oct-2026
novelty 3
per-area 2
strengthens
Relative handgrip strength and cardiometabolic multimorbidity among chinese middle-aged and older adults: mediation by metabolic and inflammatory pathways.
23-oct-2026
novelty 3
per-area 2
strengthens
Dietary Equisetum arvense Polysaccharides Alleviate Obesity in Aged Mice Associated with Altered Gut Microbiota.
23-oct-2026
novelty 2
per-area 2
strengthens
Deciphering adipaging in Drosophila: Exploring carotenoid-mediated regulation of aging and metabolism.
23-oct-2026
novelty 2
per-area 2
strengthens
Leptin Neutralization Attenuates Inflammaging in Endothelial and Immune Cell Models.
23-oct-2026
novelty 3
per-area 3
strengthens
Mechanisms of the interaction between aging of the male reproductive system and obesity, and clinical management strategies (Review).
23-oct-2026
novelty 2
per-area 2
strengthens
Sustained Versus Minimal GLP-1 Receptor Agonist Exposure and Metabolic Outcomes in Older Adults Without Diabetes.
22-oct-2026
novelty 3
per-area 3
strengthens
Thyroid dysfunction in aging and cardiovascular-kidney-metabolic syndrome: metabolic regulation and clinical implications.
22-oct-2026
novelty 2
per-area 2
strengthens
Association between SGLT2 inhibitor use and functional outcomes in elderly patients receiving ferric carboxymaltose: a retrospective observational cohort study.
21-oct-2026
novelty 2
per-area 2
strengthens
Estrogen Receptor-Mediated Effects of a Phytoestrogen-Rich Soy-Based Diet on Metabolic Health Following Ovariectomy in Aged Mice.
21-oct-2026
novelty 3
per-area 2
strengthens
Associations of longitudinal patterns of central obesity and chronic low-grade inflammation with incident frailty in middle-aged and older adults.
21-oct-2026
novelty 3
per-area 3
strengthens
Exploring Association Rules for Chronic Comorbidities in Possible Sarcopenic Obesity among Middle-aged and Older Adults: Evidence from the CHARLS 2015.
21-oct-2026
novelty 2
per-area 2
strengthens
Community-based identification of poor sleep quality in middle-aged and older adults with abdominal obesity using psychological and physical fitness indicators.
21-oct-2026
novelty 2
per-area 2
strengthens
Obesity-induced oxidative stress and cGMP depletion suppress cerebellar α2,3-Na,K-ATPase activity in female mice.
20-oct-2026
novelty 2
per-area 2
strengthens
Relative muscle mass and grip strength as complementary correlates of metabolic syndrome: a nationwide DXA-based study of Korean adults.
17-oct-2026
novelty 2
per-area 2
strengthens
Heavy inheritance: Genetic pathways from excess weight to biological aging and health in old age.
17-oct-2026
novelty 3
per-area 3
strengthens